Insmed Inc (INSM)vsKrystal Biotech Inc (KRYS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
KRYS
Krystal Biotech Inc
$254.95
+3.18%
HEALTHCARE · Cap: $7.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 56% more annual revenue ($606.42M vs $389.13M). KRYS leads profitability with a 52.6% profit margin vs -2.1%. KRYS earns a higher WallStSmart Score of 57/100 (C).
INSM
Hold39
out of 100
Grade: F
KRYS
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-57.2%
Fair Value
$173.46
Current Price
$254.95
$81.49 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 53 of every $100 in revenue as profit
Strong operational efficiency at 41.3%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
17.5% revenue growth
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 52.6% and operating margin at 41.3%. Revenue growth of 17.5% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while KRYS is a growth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
KRYS is growing revenue faster at 17.5% — sustainability is the question.
KRYS generates stronger free cash flow (75M), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (57/100 vs 39/100), backed by strong 52.6% margins and 17.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?